专注于自身免疫和炎症性疾病的早期生物技术公司 TRex Bio Inc. 正寻求通过首次公开募股（IPO）筹集高达 1.333 亿美元。
Bio Inc., an early-stage biotech focused on autoimmune and inflammatory diseases, is seeking to raise as much as $133.3 million in an initial public offering.
根据该公司周一向美国证券交易委员会（SEC）提交的文件，TRex 计划发行 830 万股，发行价区间为每股 14 至 16 美元。按该区间上限计算，根据文件中列出的流通股数，TRex 的市值将达约 4.39 亿美元。
The company plans to market 8.3 million shares for $14 to $16 each, according to its filing Monday with the US Securities and Exchange Commission. At the top of that range, TRex would have a market value of about $439 million based on the outstanding shares listed in its filing.
这家总部位于旧金山的公司的投资者包括礼来公司、SV Health Investors、辉瑞公司的风投部门辉瑞风投、强生创新、Janus Henderson Investors、Alexandria Venture Investments、Delos Capital 和 Polaris Partners。文件显示，礼来已表示有意在 IPO 中认购股份，但其持股比例不打算超过 19.9%。
The San Francisco-based firm counts Eli Lilly & Co., SV Health Investors, Pfizer Inc.’s venture capital arm Pfizer Ventures, Johnson & Johnson Innovation, Janus Henderson Investors, Alexandria Venture Investments, Delos Capital and Polaris Partners as investors. Eli Lilly has indicated an interest in buying shares in the IPO, though it doesn’t plan for its stake to exceed 19.9%, the filing shows.
据彭博新闻社看到的一份推介材料显示，该 IPO 预计将于 10 月 8 日定价。
The IPO is expected to price Oct. 8, according to a marketing presentation seen by Bloomberg News.
TRex 有望延续美国医疗保健领域首发上市的火热行情。根据彭博汇编的数据，今年以来生物技术和制药 IPO 已募集 76 亿美元，几乎是去年同期的六倍。
TRex is poised to extend a red-hot year for healthcare debuts in the US. Biotech and pharmaceutical IPOs this year have garnered $7.6 billion, nearly six times the amount raised in the same period last year, according to data compiled by Bloomberg.
根据文件，TRex 计划将募资用于推进其首款候选药物 TRB-061 的开发，该药物目前正在中重度特应性皮炎患者中进行早期临床试验。公司预计将于明年年中获得该实验性疗法的主要终点数据。此外，该生物技术公司还计划在 2027 年上半年为其治疗炎症性肠病的实验性药物 TRB-071 启动 I 期临床试验。
TRex plans to use proceeds from the offering to advance its lead drug candidate, TRB-061, which is in early-stage trials in patients with moderate-to-severe atopic dermatitis. The firm expects topline data for the experimental therapy in the middle of next year, according to the filing. The biotech also plans to enter a Phase 1 trial in the first half of 2027 for TRB-071, its experimental drug to treat inflammatory bowel disease.
据当时的一份声明称，今年 1 月，TRex 通过 B 轮优先股的额外融资募集了 5000 万美元，新投资方包括 Janus Henderson 和 Balyasny Asset Management。
In January, TRex raised $50 million from an additional closing of Series B preferred stock that included new investments from Janus Henderson and Balyasny Asset Management, according to a statement at the time.
Johnston Erwin，TRex首席执行官，在加入公司前曾在礼来公司工作36年。他此前领导Lilly New Ventures，即该制药商的内部风险投资部门。
Johnston Erwin, TRex’s chief executive officer, worked at Eli Lilly for 36 years before joining the company. He previously led Lilly New Ventures, the drugmaker’s internal venture capital investment arm.
根据早前的文件显示，这家生物技术公司2025年录得3480万美元净亏损，而一年前的净亏损为310万美元。
The biotech incurred a net loss of $34.8 million in 2025, compared with a net loss of $3.1 million a year earlier, according to an earlier filing.
此次发行由摩根大通、Evercore Inc.、Cantor Fitzgerald、Stifel Financial Corp.和Wedbush PacGrow牵头。公司预计其股票将在纳斯达克全球精选市场交易，代码为TRXB。
The offering is being led by JPMorgan Chase & Co., Evercore Inc., Cantor Fitzgerald, Stifel Financial Corp. and Wedbush PacGrow. The company expects its shares to trade on the Nasdaq Global Select Market under the symbol TRXB.